Alkaloids of fascaplysin are effective conventional chemotherapeutic drugs, inhibiting the proliferation of C6 glioma cells and causing their death in vitro

Bryukhovetskiy,Igor; Lyakhova,Irina; Mischenko,Polina; Milkina,Elena; Zaitsev,Sergei; Khotimchenko,Yuri; Bryukhovetskiy,Andrey; Polevshchikov,Alexander; Kudryavtsev,Igor; Khotimchenko,Maxim; Zhidkov,Maxim

doi:10.3892/ol.2016.5478

Alkaloids of fascaplysin are effective conventional chemotherapeutic drugs, inhibiting the proliferation of C6 glioma cells and causing their death in vitro

Authors:
- Igor Bryukhovetskiy
- Irina Lyakhova
- Polina Mischenko
- Elena Milkina
- Sergei Zaitsev
- Yuri Khotimchenko
- Andrey Bryukhovetskiy
- Alexander Polevshchikov
- Igor Kudryavtsev
- Maxim Khotimchenko
- Maxim Zhidkov
View Affiliations

Affiliations: Laboratory of Molecular and Cellular Neurobiology, School of Biomedicine, Far Eastern Federal University, Vladivostok 690091, Russian Federation, Department of Basic Medicine, School of Biomedicine, Far Eastern Federal University, Vladivostok 690091, Russian Federation, Department of Pharmacy, School of Biomedicine, Far Eastern Federal University, Vladivostok 690091, Russian Federation, Department of Bioorganic Chemistry, School of Natural Sciences, Far Eastern Federal University, Vladivostok 690091, Russian Federation
Published online on: December 9, 2016 https://doi.org/10.3892/ol.2016.5478
Pages: 738-746
Copyright: © Bryukhovetskiy et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma multiforme is an invasive malignant glial brain tumor with a poor prognosis for patients. The primary reasons that lead to the development of treatment resistance are associated with tumor cells infiltrating the brain parenchyma and the specific properties of tumor stem cells. A crucial research area in medical science is the search for effective agents that are able to act on these targets. Fascaplysin alkaloids possess potent antitumor activity. Modern methods for the targeted delivery of drugs reveal extensive possibilities in terms of the clinical use of these compounds. The aim of the present study was to establish effective concentrations of fascaplysin that inhibit the growth and kill the cells of glial tumors, as well as to perform a comparative analysis of fascaplysin's effectiveness in relation to other chemotherapy drugs. C6 glioma cells were utilized as an optimal model of glioblastoma. It was established that fascaplysin at 0.5 µM has a strong cytotoxic effect, which is subsequently replaced by tumor cell death via apoptosis as the length of drug exposure time is increased. Fascaplysin kills glioma cells at a dose higher than 0.5 µM. The efficiency of fascaplysin was observed to significantly exceed that of temozolomide. Therefore, a significant feature of fascaplysin is its ability to inhibit the growth of and kill multipotent tumor cells.

View Figures

View References

1	Carlsson SK, Brothers SP and Wahlestedt C: Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med. 6:1359–1370. 2014. View Article : Google Scholar : PubMed/NCBI
2	Omuro A and DeAngeles LM: Glioblastoma and others malignant gliomas: A clinical review. JAMA. 310:1842–1850. 2013. View Article : Google Scholar : PubMed/NCBI
3	Anton K, Baehring JM and Mayer T: Glioblastoma multiforme: Overview of current treatment and future perspectives. Hematol Oncol Clin North Am. 26:825–853. 2012. View Article : Google Scholar : PubMed/NCBI
4	Konovalov AN, Potapov AA, Loshakov VA, Olyushin VE, Ulitin AY, Kornienko VN, Pronin IN, Shishkina LV, Golanov AV, Tanqskiu SV, Urakov SV and Kobqkov GL: Association of Neurosurgeons of Russia: The standards, guidelines and options in the treatment of brain tumors in adults (2009). Association of Neurosurgeons of Russia; Moscow, Russia: 2009, (In Russian).
5	Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, et al: International Society of Neuropathology - Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 24:429–435. 2014. View Article : Google Scholar : PubMed/NCBI
6	Paw I, Carpenter RC, Watabe K, Debinski W and Lo HW: Mechanisms regulating glioma invasion. Cancer Lett. 362:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
7	Molina JR, Hayashi Y, Stephens C and Georgescu MM: Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia. 12:453–463. 2010. View Article : Google Scholar : PubMed/NCBI
8	Barani IJ and Larson DA: Radiation therapy of glioblastoma. Cancer Treat Res. 163:49–73. 2015. View Article : Google Scholar : PubMed/NCBI
9	Mitchison TJ: The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell. 23:1–6. 2012. View Article : Google Scholar : PubMed/NCBI
10	Xu YY, Gao P, Sun Y and Duan YR: Development of targeted therapies in treatment of glioblastoma. Cancer Biol Med. 12:223–237. 2015.PubMed/NCBI
11	Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P and Bannerjee SK: Drug delivery systems: An updated review. Int J Pharm Investig. 2:2–11. 2012. View Article : Google Scholar : PubMed/NCBI
12	Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, et al: Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas. Proc Natl Acad Sci USA. 97:12846–12851. 2000. View Article : Google Scholar : PubMed/NCBI
13	Zhou J, Atsina KB, Himes BT, Strohbehn GW and Saltzman WM: Novel delivery strategies for glioblastoma. Cancer J. 18:89–99. 2012. View Article : Google Scholar : PubMed/NCBI
14	Barber FA: Complications of Biodegradable Materials: Anchors and Interference Screws. Sports Med Arthrosc. 23:149–155. 2015. View Article : Google Scholar : PubMed/NCBI
15	Roll DM, Ireland CM, Lu HSM and Clardy J: Fascaplysin, an unusual antimicrobial pigment from the marine sponge Fascaplysinopsis sp. J Org Chem. 53:3276–3278. 1988. View Article : Google Scholar
16	Bharate SB, Manda S, Mupparapu N, Battini N and Vishwakarma RA: Chemistry and biology of fascaplysin, a potent marine-derived CDK-4 inhibitor. Mini Rev Med Chem. 12:650–664. 2012. View Article : Google Scholar : PubMed/NCBI
17	Kuzmich AS, Fedorov SN, Shastina VV, Shubina LK, Radchenko OS, Balaneva NN, Zhidkov ME, Park JI, Kwak JY and Stonik VA: The anticancer activity of 3- and 10-bromofascaplysins is mediated by caspase-8, −9, −3-dependent apoptosis. Bioorg Med Chem. 18:3834–3840. 2010. View Article : Google Scholar : PubMed/NCBI
18	Lu XL, Zheng YL, Chen HM, Yan XJ, Wang F and Xu WF: Anti-proliferation of human cervical cancer HeLa cell line by fascaplysin through apoptosis induction. Yao Xue Xue Bao. 44:980–986. 2009.(In Chinese). PubMed/NCBI
19	Hamilton G: Cytotoxic effects of fascaplysin against small cell lung cancer cell lines. Mar Drugs. 12:1377–1389. 2013. View Article : Google Scholar
20	Phillips MA, Gran ML and Peppas NA: Targeted nanodelivery of drugs and diagnostics. Nano Today. 5:143–159. 2010. View Article : Google Scholar : PubMed/NCBI
21	Zhidkov ME and Kaminskii VA: A new method for the synthesis of marine alkaloid fascaplysin based on the microwave-assisted Minisci reaction. Tetrahedron Lett. 54:3530–3532. 2014. View Article : Google Scholar
22	Kirsch G, Köng GM, Wright AD and Kaminsky R: A new bioactive sesterterpene and antiplasmodial alkaloids from the marine sponge hyrtios cf. erecta. J Nat Prod. 63:825–829. 2000. View Article : Google Scholar : PubMed/NCBI
23	Idziorek T, Estaquier J, De Bels F and Ameisen JC: YOPRO-1 permits cytofluorometric analysis of programmed cell death (apoptosis) without interfering with cell viability. J Immunol Methods. 185:249–258. 1995. View Article : Google Scholar : PubMed/NCBI
24	Fujisawa S, Romin Y, Barlas A, Petrovic LM, Turkekul M, Fan N, Xu K, Garcia AR, Monette S, Klimstra DS, et al: Evaluation of YO-PRO-1 as an early marker of apoptosis following radiofrequency ablation of colon cancer liver metastases. Cytotechnology. 66:259–273. 2014. View Article : Google Scholar : PubMed/NCBI
25	Rieger AM, Nelson KL, Konowalchuk JD and Barreda DR: Modified annexin V/propidium iodide apoptosis assay for accurate assessment of cell death. J Vis Exp. 50:2512011.
26	Kudryavtsev IV, Khaidukov SV, Zurochka AV and Chereshev VA: Flow cytometry in experimental biology. RIO Ural Branch of the Russian Academy of Sciences; Yekaterinburg, Russia: 2012, (In Russian).
27	Hughes D and Mehmet H: Cell Proliferation and Apoptosis. 1st. Taylor and Francis; Abingdon, UK: 2002
28	Kostaras X, Cusano F, Kline GA, Roa W and Easaw J: Use of dexamethasone in patients with high-grade glioma: A clinical practice guideline. Curr Oncol. 21:e493–e503. 2014. View Article : Google Scholar : PubMed/NCBI
29	Chamberlain MC: Temozolomide: Therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother. 10:1537–1544. 2010. View Article : Google Scholar : PubMed/NCBI
30	Chen TC, Cho HY, Wang W, Wetzel SJ, Singh A, Nguyen J, Hofman FM and Schönthal AH: Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo. J Biomed Sci. 22:712015. View Article : Google Scholar : PubMed/NCBI
31	Zeiss CJ: The apoptosis-necrosis continuum: Insights from genetically altered mice. Vet Pathol. 40:481–495. 2003. View Article : Google Scholar : PubMed/NCBI
32	Zhang X, Zhang W, Cao WD, Cheng G and Zhang YQ: Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review). Exp Ther Med. 3:9–14. 2012.PubMed/NCBI
33	Kalkan R: Glioblastoma stem cells as a new therapeutic target for glioblastoma. Clin Med Insights Oncol. 9:95–103. 2015. View Article : Google Scholar : PubMed/NCBI
34	Bryukhovetskiy A, Shevchenko V, Kovalev S, Chekhonin V, Baklaushev V, Bryukhovetskiy I and Zhukova M: To the novel paradigm of proteome-based cell therapy of tumors: Through comparative proteome mapping of tumor stem cells and tissue-specific stem cells of humans. Cell Transplant. 23:(Suppl 1). S151–S170. 2014. View Article : Google Scholar : PubMed/NCBI
35	Khalili AA and Ahmad MR: A Review of Cell Adhesion Studies for Biomedical and Biological Applications. Int J Mol Sci. 16:18149–18184. 2015. View Article : Google Scholar : PubMed/NCBI
36	Park D, Xiang AP, Mao FF, Zhang L, Di CG, Liu XM, Shao Y, Ma BF, Lee JH, Ha KS, et al: Nestin is required for the proper self-renewal of neural stem cells. Stem Cells. 28:2162–2171. 2010. View Article : Google Scholar : PubMed/NCBI
37	Barth RF and Kaur B: Rat brain tumor models in experimental neuro-oncology: The C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol. 94:299–312. 2009. View Article : Google Scholar : PubMed/NCBI
38	Zhang PY, Yang YJ, Xue Y, Fu J, Zhang CX, Wang Y, Yang Y and Shi H: Cancer stem cells: Targeting tumors at the source. Eur Rev Med Pharmacol Sci. 19:1821–1828. 2015.PubMed/NCBI
39	Xie Q, Mittal S and Berens ME: Targeting adaptive glioblastoma: An overview of proliferation and invasion. Neuro Oncol. 16:1575–1584. 2014. View Article : Google Scholar : PubMed/NCBI
40	Paltsev MA, Ivanov AA and Severin SE: Cellular interactions (2nd). Medicine. Moscow: 2003.(In Russian).
41	Wolinsky JB, Colson YL and Grinstaff MW: Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J Control Release. 159:14–26. 2012. View Article : Google Scholar : PubMed/NCBI
42	Meng XG and Yue SW: Dexamethasone disrupts cytoskeleton organization and migration of T47D human breast cancer cells by modulating the AKT/mTOR/RhoA pathway. Asian Pac J Cancer Prev. 15:10245–10250. 2014. View Article : Google Scholar : PubMed/NCBI
43	Laquintana V, Trapani A, Denora N, Wang F, Gallo JM and Trapani G: New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv. 6:1017–1032. 2009. View Article : Google Scholar : PubMed/NCBI
44	Friedman HS, Kerby T and Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res. 6:2585–2597. 2000.PubMed/NCBI
45	Zhang J, Stevens MF and Bradshaw TD: Temozolomide: Mechanisms of action, repair and resistance. Curr Mol Pharmacol. 5:102–114. 2012. View Article : Google Scholar : PubMed/NCBI
46	Bryukhovetsky IS: The effectiveness in vivo of a stem cell drug on glioblastoma rat's model after chemotherapy. Russian Journal of Biotherapy. 13:51–58. 2014.(In Russian).